Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCLEPIuS: Niraparib + SBRT + Abiraterone + Leuprolide in High Risk Prostate Cancer
NCT04194554Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2020
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in prostate cancer (PCa), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Dose-limiting toxicities at 112 days and Proportion of patients experiencing biochemical failure at 3 years. Started Nov 2020; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04194554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194554.